AI Article Synopsis
- A study evaluated the cognitive effectiveness of xanomeline, a muscarinic agonist, in patients with mild-to-moderate Alzheimer’s disease using two assessment tools: the CNTB and the ADAS-cog, over a 24-week period with follow-up observation.
- The results indicated that while xanomeline showed a significant benefit at the highest dose for the CNTB summary score compared to placebo, a different pattern emerged in the completer analysis for the ADAS-cog.
- The CNTB demonstrated greater sensitivity across all patient impairments, highlighting that it might provide a more objective assessment of cognitive changes compared to the ADAS-cog, particularly during the placebo washout phase.*
Article Abstract
The cognitive efficacy of the M1-selective muscarinic agonist xanomeline in mild-to-moderate Alzheimer disease (AD) was measured using the Computerized Neuropsychological Test Battery (CNTB) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) in this 17-center, double-blind, placebo-controlled study. Three hundred forty-three patients were randomly assigned to receive 25, 50, or 75 mg xanomeline tartrate or placebo three times daily (t.i.d.) for 24 weeks, followed by placebo for 4 weeks in a single-blind washout phase. Cognitive function was assessed at randomization and after 4, 8, 12, 24, and 28 weeks. Three hundred nineteen patients were included in an intent-to-treat (ITT) analysis; 209 completers had evaluable data at week 24. ITT analysis showed a significant (p < or = 0.05) dose-response trend and a significant (p < or = 0.05) between-group comparison favoring 75 mg t.i.d. over placebo for the CNTB summary score but not for the ADAS-cog. In the completer analysis, however, the ADAS-cog showed a significant (p < or = 0.05) dose-response trend and between-group comparison, whereas the CNTB Summary Score did not. The ADAS-cog was less sensitive to treatment effects in mildly impaired patients (ADAS-cog < 21) than in moderately impaired patients (ADAS-cog > or = 21), whereas the CNTB was sensitive in the entire study population (mean ADAS-cog = 22.5+/-9.6). Significant (p < or = 0.05) beneficial treatment effects were seen in measures of simple reaction time and delayed verbal recall, which are included in the CNTB but not in the ADAS-cog. During the single-blind placebo washout period, the ADAS-cog score of the placebo group worsened dramatically (change of 2.63 points; p < or = 0.001), whereas the CNTB score remained stable (change of 1.04 points; p=0.694). Thus, the CNTB appears to be more objective than the ADAS-cog.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00002093-199812000-00010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-domain Online Therapeutic Investigation of Neurocognition (MOTION) - A randomized comparative-effectiveness study of two remotely delivered mind-body interventions for older adults with cognitive decline.
Contemp Clin Trials
January 2025
Department of Neurology, University of California, Los Angeles, United States of America.
Background: Research suggest that mind-body movement programs have beneficial effects on cognitive outcomes for older adults with cognitive decline. However, few studies have directly compared specific approaches to mind-body movement or studied the impact of remote program delivery.
Methods: In a 3-arm randomized controlled trial (RCT) for older adults with cognitive impairment, we are comparing a multidomain mind-body program that emphasizes movement, body awareness, personal meaningfulness, and social connection, and a traditional Chinese mind-body exercise (Tai Chi) to a health and wellness education control condition.
Objectives: Numerous studies have examined the effects of physical activity on cognitive performance and executive function in people with Alzheimer's disease (AD), although the findings are not entirely consistent. There are also insufficient study reviews for specific workout and assessment tool types. Therefore, the purpose of this study was to systematically investigate the effects of aerobic exercise on the quality of life, cognitive performance and depressive symptoms in people with AD.
View Article and Find Full Text PDFThe Correlations between Volume Loss of Temporal and Subcortical Functional Subregions and Cognitive Impairment at Various Stages of Cognitive Decline.
J Integr Neurosci
December 2024
Department of Radiology, Affiliated Hospital of North Sichuan Medical College, 637000 Nanchong, Sichuan, China.
Background: The relationship between subregion atrophy in the entire temporal lobe and subcortical nuclei and cognitive decline at various stages of Alzheimer's disease (AD) is unclear.
Methods: We selected 711 participants from the AD Neuroimaging Initiative (ADNI) database, which included 195 cases of cognitively normal (CN), 271 cases of early Mild cognitive impairment (MCI) (EMCI), 132 cases of late MCI (LMCI), and 113 cases of AD. we looked at how subregion atrophy in the temporal lobe and subcortical nuclei correlated with cognition at different stages of AD.
Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.
Neurology
January 2025
From the Institute for Memory Impairments and Neurological Disorders (J.D.G., S.T., G.T., B.V., K.G., D.L.G.), University of California, Irvine; Department of Psychiatry and Human Behavior (J.D.G.), University of California, Irvine; Department of Neurobiology and Behavior (J.D.G., K.G.), University of California, Irvine; Division of Geriatric Medicine (S.T.), Department of Medicine, University of California, Irvine; Department of Neurology (G.T.), University of California, Irvine; Department of Neurology (A.L.P.), Oregon Health and Science University; Department of Statistics (D.L.G.), University of California, Irvine; Department of Neurology and Neurological Sciences (E.T.), Stanford University; Department of Neurology (S.K.), Cedars Sinai Medical Center; Department of Neurology (M.B.), University of California, Los Angeles; Alzheimer's Disease Cooperative Study (R.A.R., G.C.L., A.B., C.R., R.M., R.J., J.P., J.Z., S.J., K.M., H.H.F.), University of California, San Diego; and Department of Neurosciences (G.C.L., J.P., H.H.F.), University of California, San Diego.
Background And Objectives: Nicotinamide is a coenzyme involved in cellular oxidation-reduction reactions that can inhibit Class III histone deacetylases (HDACs) or sirtuins. HDAC inhibition can affect numerous therapeutic pathways, including tau phosphorylation. We tested the hypothesis that nicotinamide treatment could reduce tau phosphorylation in early Alzheimer disease (AD).
View Article and Find Full Text PDFDiscovery of the microbiota-gut-brain axis mechanisms of acupuncture for amnestic mild cognitive impairment based on multi-omics analyses: A pilot study.
Complement Ther Med
December 2024
School of Acu-Mox and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China; Sichuan Provincial Acupuncture Clinical Medicine Research Center, Chengdu, China. Electronic address:
Objectives: Acupuncture is a promising therapy for amnestic mild cognitive impairment (aMCI). Growing evidence suggest that alterations in the microbiota-gut-brain (MGB) axis contribute to the development and progression of aMCI. However, little is known about whether and how acupuncture change the MGB axis of aMCI individuals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!